The primary aim of this exploratory study was to analyse the design factors contributing to the reading ease and comprehension of medicinal information leaflets. Good practice guidelines on general typography and layout were chosen from the literature and compared with European Commission guidelines on preparing package leaflets. The suitability of the guidelines for evaluating package inserts was investigated using leaflets accompanying thirteen different medicines available from pharmacies. With minor revision, the design recommendations were appropriate for developing over the counter medicinal leaflets. There was general agreement that simplicity is the key to good information design. It was concluded that the design of readable medicinal package inserts is a complex, process. Consumer participation is essential and advice from a professional designer highly desirable.
Introduction
Patients are being encouraged by recent government initiatives to take greater personal responsibility, in partnership with appropriate professionals, for health care decisions (Department of Health, 1997a; 2000) . Consumer choice has increased in the last decade with legislative action allowing a wider range of more potent medicines previously only available on prescription being reclassified for sale in pharmacies (Blenkinsopp & Bradley, 1996) . Access to high quality information is essential if these drugs are to be used safely and effectively without clinical supervision.
Since 1998 all UK medicinal products, whether dispensed by a pharmacist or bought over the counter, have to be supplied with an authorised patient information leaflet (European Commission, 1992; Medicines Control Agency, 1998a) . Manufacturers need to compile leaflets that comply with this legislation, fit into the drug packaging and are understood by a general population with diverse abilities and needs (Griffin & Griffin, 1996) . The few studies that have evaluated the quality of medicinal package inserts (Bradley, 1994; Wong, 1999) have used readability formulae as assessment tools but these are limited in their scope for improving Table 1 : Good practice guidelines on patient leaflet design and typography Paper A5 size is preferable A leaflet is more likely to be kept if it is a convenient size e.g. able to fit in a medicine bag or pocket Non-transparent paper Text showing through from the reverse side makes letters and words difficult to distinguish Matt surface Glossy paper makes reading difficult by reflecting too much light
Layout
Consistent use of layout Consistent organisation within the leaflet gives visual clues to the proximity and grouping of textual elements and headings Plenty of white space A page of close-set type easily daunts readers and there is a long tradition in design that the 4 margins are never equal in width Type size Ensuring the suitability of type for a particular audience has long been a main principle of typography (Orna & Stevens, 1995) . The Royal National Institute for the Blind (1997) uses 12-point text to produce documents intended for general readers and believes others should aspire to this level of print size, in agreement with the National Information Forum (1996) . Independent studies reviewed by Hartley (1999) have shown that a type size of 12-or 14-point is helpful to older readers. A minimum of 14-point is advised for materials aimed at partially sighted and blind people, a significant proportion of whom can read large print (Royal National Institute for the Blind, 1997) but use of this size could make the PIL appear too long for the 'average' reader. Additionally, according to the Basic Skills Agency (1999) too large a print can deter adults with reading difficulties as the material may look as though it is intended for children. Therefore, 12-point type size has been adopted as a benchmark in this study.
Justification Justified text (straight edged left and right margins) causes 'rivers' of white space to appear as the gaps between words are adjusted to fill the line length so the eye has difficulty linking words together and slows down reading (Orna & Stevens, 1995) . Thus, the Royal National Institute for the Blind (1997) prefers unjustified text (jagged right-hand margin). Although Hartley (1999) asserts that research suggests there is little to choose between the two and is largely a matter of style, he does concede that unjustified text is probably more flexible for information leaflets. Therefore unjustified right-hand margins has been used as the standard in this study.
Official guidelines
Advice given by the regulators on page size, paper type, headings and emphasis (EC, 1998) does not differ significantly from the literature guidelines with two main exceptions. The EC (1998) recommends the rather low minimum of 8-point type and this affects their advice on inter-line spacing (at least 3mm). It is also suggested that sentences with more than 20 words should be avoided and lines with more than 70 characters not used but the basis for these statements is not referenced. However, authoritative sources (Orna & Stevens, 1995; Plain English Campaign, 1998 ; Royal National Institute for the Blind, 1997) recommend more moderate line lengths for ease of reading, even in continuous text, leading to the guidance in Table 1 . The authorities (EC, 1998) give no or very general advice on margins, white space, column widths, paragraph spacing, typefaces and justification. The official directions regarding illustrations are limited. They are allowed only in addition to text if they help understanding and they must not be promotional.
Package insert case studies
Nineteen prescription medicines containing different active ingredients were identified as having changed legal status to pharmacy sale between 1993 and 1998. Photocopies of package inserts were obtained for thirteen medicines whose details are shown in Table 2 . The other PILs were not available because the pharmacist who provided the leaflets did not stock two of the products, did not know the legal status had changed in one case and could not open three packs as they had security seals. *Denotes year when the legal change to pharmacy sale was made; the product was not necessarily marketed in the same year ♦ This is the date of the leaflet included in the package at the time of the study (1999)
Page and paper characteristics All the leaflets were printed on single sheets but had a wide range of dimensions. Most (9/13) were close in area to A5 whilst the remainder were smaller. There was some correlation between the area of the leaflet and the pharmaceutical form and quantity of the product. For example, one of the smallest products, Adcortyl 5g paste, contained a leaflet half the area of the insert supplied with one of the largest products, Nizoral 60ml shampoo. However, very similar products, e.g. Feldene and Solpaflex, had very different size leaflets indicating other factors were influencing the dimensions of the insert. Four leaflets were transparent but the measure used in this study was rather insensitive so this figure may increase when the original leaflets are viewed. All the PILs had a matt surface.
Layout Formats were used consistently except where illustrations were included. To maximise the use of space, the format had to vary in the Rhinolast, Syntaris, Traxam and Zovirax leaflets to accommodate text that related directly to the diagrams. Two thirds (10/13) of the leaflets had a portrait style orientation and most (6/10) of these used a single-column text only format, as Hartley (1999) found with prescription PILs. In other leaflets with diagrams, one used landscape and two used portrait. The sample is too small to confirm the conclusion of Hartley (1999) that landscape orientation is more likely to be used when there is a need for illustrations and two-column text.
Separation between columns was judged to be adequate ranging from 4 to 6mm. This is equivalent to 2-3 times the total type size although this was small (point 6-7) in this group of PILs. Vertical lines were not used to separate columns in any of the relevant leaflets. Margins could not be measured as these did not show clearly enough on the photocopied leaflets. Additionally, whether the amount of white space was adequate is probably a matter of opinion, best resolved by evaluation of the original PILs with consumers and graphic designers.
Type size No leaflets had type as large as 12-point although two (Nizoral and Feldene) had 11-point type. Four had 8 to 10-point and seven had 6 to 7-point type. Thus, half of the leaflets used a print size lower even than the EC guidelines (1998). However, all the leaflets were prepared before these guidelines became effective in January 1999. Two leaflets with 6-point type were about half A5 size and accompanied small volume products (Adcortyl and Corlan) used for mouth ulcers. Increasing the area of these PILs to allow larger type may be difficult due to the small size of their packaging. The remaining PILs that had very small type contained illustrations.
Typeface None of the PILs had bizarre, unusual or indistinct typefaces. Nearly all the leaflets (12/13) use normal type for most of the text and the bold version for the headings. Nonetheless, this applies to typeface only and does not reflect the less simple use of colour, capitals and boxing used in some PILs.
Inter-line spacing None had an inter-line space of 5mm or more but the spaces used were all related to the print size and consistent with the 125% rule of thumb. All the PILs had unjustified right-hand margins. This is probably the best solution for these leaflets, as they do not contain much prose text and the sense often demands short lines.
Line lengths
The line lengths for each sample leaflet varied considerably so the length of the longest line in each leaflet was taken as a very rough measure. Most (9/13) PILs that had single columns of text had much longer lines (range 13-20 words; 68-132 characters) than the recommendation for prose text (8-11 words; 50-65 characters). Two single column PILs came within the advised range but one was a long narrow leaflet (Diflucan) and the other (Feldene) had one of the largest type sizes (11-point). The remaining leaflets falling within the recommended range had two columns of text (Pepcid and Traxam).
Headings As for prescription drug leaflets (Patient i, 1997), the majority of the leaflets (10/13) used left-ranging headings with the remainder having centred ones. Most inserts had two or less headings and used typographic and colour cues consistently. However, this is not as simple as it sounds. Seven PILs had obvious headings that were clearly distinguishable from the text. Others had consistent use of headings but multiple cueing systems, using a combination of bold and italic print with variations of colours, capitals and boxing, which appeared confusing. In others, similar devices were used for emphasis of important information and it was difficult to differentiate these from the headings. There was no obvious connection between the use of 'complex' headings and the treatment uses of the medicines. These PILs were prepared only slightly earlier (median 1995) than those with 'simple' headings (median 1996).
The newest leaflet, Motilium prepared in June 1998, was the only one to have numbered headings whilst none had a table of contents. This is not surprising since this advice from the European Commission (1998) post-dates all of the PILs. Bullet point summaries were present at some point in nearly all of the leaflets (10/13) although they were only used extensively in two (Motilium and Syntaris). Eight PILs had bullet points for the 'precautions' section only.
Emphasis Capitals were used in almost half the leaflets for headings (6/13) and three had complete sentences in capitals to indicate warnings. As research suggests lower case letters are easier to read (Hartley, 1994) , manufacturers would be wise to avoid unnecessary capitals for important information and for long headings (European Commission, 1998) . All the leaflets had bold headings.
The text of two PILs (Feldene and Nizoral) did not contain any emphasised areas. In the remainder attention was drawn to the content in the following ways (number of leaflets in brackets): bold type (11), capitals (7), boxing (5), colour (4), underlining (2) and italic type (1). However, only three PILs had simple devices. Some had quite complex arrangements; for example, boxing, colour, bold type and capitals highlighted single warnings in the Rhinolast and Syntaris leaflets. The product name was printed in capitals or bold type in five leaflets. This may not accord with minimisation of the brand name as indicated by the EC (1998).
Colour All the leaflets except one had a white background. Most (8/13) had black print on white paper whilst four had royal blue print. The Diflucan leaflet had a two-tone blue background and purple print, probably the worst combination for making reading difficult (Basic Skills Agency, 1999) . Only the Rhinolast and Zovirax leaflets had another colour typeface and this was reserved for the headings. However, since the headings were also printed in bold type or boxed, an extra colour, of whatever hue, is possibly unnecessary. Yellow ink was used in the headings and illustrations in two leaflets (Traxam and Syntaris) counter to the advice of the Royal National Institute for the Blind (1997).
Illustrations None of the PILs were printed over pictures or had text wrapped around the illustrations. Six PILs had illustrations: three using diagrams, two using pictograms and one using both.
Using the guidelines
The guidelines were developed with the aim of helping to produce planned, simple and clear documents focused on the needs of users. Using the study PILs allowed these guidelines to be revised to accommodate the particular circumstances of package inserts:
• the advice given for maximum line length was difficult to apply since the length of lines in the leaflets varied considerably • consistency in the use of headings alone did not always help the appearance of a document. Therefore, this advice should be extended to include headings clearly differentiated from the text in accordance with simplicity (Hartley, 1999) .
The designs ranged from 'simple' ones that mainly followed the guidelines to much more complex arrangements. For example, the PIL for Feldene (pain relief gel) had 11-point type and simple bold headings clearly differentiated from the text. Black instead of blue print and bullet points may improve its readability. The insert for Syntaris (for hayfever) was much more complex with 7-point type, more than two typefaces, sentences in italic and wide use of capitals, bold type, boxing and colour. Although this leaflet contains possibly useful diagrams on how to use the nasal spray it could still be simplified by following the guidelines.
This investigation was essentially exploratory and did not expect to reach overall conclusions on the design success, or otherwise, of OTC medicinal leaflets. However, small changes in some PILs could be tested with consumers immediately. Reducing the very large symbol that dominates the first page would considerably shorten the Tagamet leaflet. Yellow ink used in the headings and illustrations in the Traxam and Syntaris inserts could be replaced with a darker colour to increase readability. None of the leaflets examined displayed the Crystal Mark awarded by the Plain English Campaign (1998) as a guarantee of a document's clarity of design as well as clearly and plainly written text. It is unknown whether the pharmaceutical companies involved had applied for the award.
Discussion
There was general agreement amongst those committed to communicating information to members of the public of the fundamentals of good design. Although Stevens (1991, 1995) state that the principles of typographic design are based on well-founded research, the evidence base for the guidelines reported here requires systematic review. However, this should be undertaken within the context of document design being mainly a problem-solving task operating within the constraints of content, space, time and budget. The skill and flair of a professional designer may be required whilst organisations such as the Plain English Campaign (1998) offer guidance on communicating clearly and effectively. However, the final decisions should be based on consumer evaluation.
The benchmarks were chosen so that the design of the leaflet made it accessible to as many people as possible including older people and those with literacy problems. They will not cater for non-English speakers, many blind consumers and people with learning difficulties. It would be impractical to expect manufacturers to supply leaflets for all these groups in the packaging but some mechanism allowing access to drug information for these members of society needs investigation.
This study raised the difficulty of obtaining leaflets accompanying OTC medicines, whether the originals or copies, without expense or personal contacts. A widely available compendium of OTC package inserts as exists for prescribed medicines (Walker, 1999) would benefit consumers as well as health professionals. PILs could not be obtained for six products but the sample assessed represented the main reasons consumers use an OTC medicine (Blenkinsopp & Bradley, 1996) and a range of manufacturers.
Although the sample of PILs produced by OTC manufacturers was very varied, the pooled published guidelines were generally suitable for assessing the design of drug package inserts. However, the recommendation of a maximum line length of 50-65 characters was not easily applied to this type of leaflet. Some guidance on line length is needed but it is dependent on the initial choice of layout, such as single or double columns of text. Newton et al. (1998) found that single column text was preferred to newspaper-style columns in a leaflet on gout but further investigation is required with package inserts. Examination of the sample leaflets also showed that headings need to be used not only consistently but also clearly separated from the text if they are to act as good navigational aids.
The advice to use 'plenty of white space' was kept in the guidelines although it is difficult to assess and is probably best determined by consulting consumers and designers. A better indicator for the measure of transparency than the one used in this study would be the weight of the paper (g/m 2 ), given the availability of appropriate weighing equipment. The EC (1998) recommends a minimum weight of 40g/m 2 statement but the opacity of this weight requires confirmation. However, thicker paper may make the PILs more difficult to fold and fit into the packs.
Overall, this study confirmed previous advice (Basic Skills Agency, 1999; Hartley, 1994; Orna & Stevens, 1995 ; Royal National Institute for the Blind, 1997 ) that the initial choice of page size and the decision to include diagrams is important since it affects many subsequent design characteristics, especially type size. About half the inserts did not follow the recommendations for simplicity and clarity. Considerable variation in size, shape, typography and layout was evident in the sample OTC leaflets, confirming previous findings with prescription medicine leaflets (Hartley, 1999) . None of the sample had a type size as large as that recommended by the Royal National Institute for the Blind (1997) for adult readers. However, increasing type size, and associated inter-line spacing, would make the PIL longer. Type size, the usefulness of illustrations and the devices used to emphasise headings and warnings require further investigation with consumers to establish best practice. The EC (1998) has indicated that it is open to making changes in the legislation if they are shown to improve readability.
Conclusions
Production of patient package inserts is a complex, process requiring regulatory approval. As this is the first study to investigate the design of OTC medicinal package inserts more questions than answers were raised. The following areas would benefit from more detailed research:
• the evidence underpinning the guidelines compiled in this study • evaluation by consumers of the readability of PILs revised using the good design guidelines • user preference regarding the style of layout and typography, especially type size, and the use of illustrations in medicinal package inserts and the consequent effects on comprehension • the effect of consumer involvement on the design of medicinal PILs • the value for pharmaceutical companies of consulting a professional information designer and the Plain English Campaign when drafting package inserts Following establishment of the most effective layout and typography, approaches should be made to the European Commission and Medicines Control Agency to supplement or change the guidance given to manufacturers for the preparation of patient information leaflets. Good information design is important but attention to this alone does not produce high quality patient information leaflets. Well written text, evidence-based information and consumer testing are also essential.
